STAT Virtual Event: The State of Biosimilars: What to Watch
Join STAT for a discussion of what's next for biosimilars, and what key signals will indicate how they might be prescribed, or paid for.
Editor’s note: A recording of the event is embedded below.
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?
What's Your Reaction?
